

Kiran Musunuru

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8759507/kiran-musunuru-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

14,109
citations

42
h-index

118
g-index

133
ext. papers

17,093
ext. citations

13.6
avg, IF

6.27
L-index

#	Paper	IF	Citations
118	Biological, clinical and population relevance of 95 loci for blood lipids. <i>Nature</i> , 2010 , 466, 707-13	50.4	2742
117	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. <i>Lancet, The</i> , 2012 , 380, 572-80	40	1523
116	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. <i>Nature Genetics</i> , 2011 , 43, 333-8	36.3	1394
115	From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. <i>Nature</i> , 2010 , 466, 714-9	50.4	820
114	Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. <i>Nature Communications</i> , 2016 , 7, 12429	17.4	619
113	Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. <i>New England Journal of Medicine</i> , 2010 , 363, 2220-7	59.2	485
112	Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. <i>Nature Communications</i> , 2015 , 6, 8715	17.4	410
111	A TALEN genome-editing system for generating human stem cell-based disease models. <i>Cell Stem Cell</i> , 2013 , 12, 238-51	18	407
110	Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. <i>Cell Stem Cell</i> , 2014 , 15, 27-30	18	394
109	Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. <i>Cell Stem Cell</i> , 2013 , 12, 393-4	18	391
108	A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. <i>Nature Biotechnology</i> , 2016 , 34, 334-8	44.5	360
107	Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. <i>Circulation Research</i> , 2014 , 115, 488-92	15.7	345
106	Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. <i>Cell Stem Cell</i> , 2014 , 15, 643-52	18	324
105	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017 , 49, 1758-1766	36.6	310
104	Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4154-61	15.9	252
103	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2054-2063	15.1	226
102	Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. <i>Lipids</i> , 2010 , 45, 907-14	1.6	182

101	Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2807-16	15.9	151
100	In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 1741-1747	9.4	128
99	Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1975-80	9.4	113
98	In utero CRISPR-mediated therapeutic editing of metabolic genes. <i>Nature Medicine</i> , 2018 , 24, 1513-1518	50.5	112
97	Human Germline Genome Editing. <i>American Journal of Human Genetics</i> , 2017 , 101, 167-176	11	105
96	Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. <i>Cell Stem Cell</i> , 2017 , 20, 558-570.e10	18	102
95	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. <i>Circulation Research</i> , 2016 , 118, 579-85	15.7	98
94	In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. <i>Nature</i> , 2021 , 593, 429-434	50.4	96
93	Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e000043	5.2	95
92	The use of high-sensitivity assays for C-reactive protein in clinical practice. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 621-35		95
91	Genome editing of human pluripotent stem cells to generate human cellular disease models. <i>DMM Disease Models and Mechanisms</i> , 2013 , 6, 896-904	4.1	94
90	Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. <i>Cell Stem Cell</i> , 2017 , 20, 547-557.e7	18	86
89	CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 783-6	9.4	85
88	Genetics of Common, Complex Coronary Artery Disease. <i>Cell</i> , 2019 , 177, 132-145	56.2	84
87	Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition. <i>Nature Genetics</i> , 2018 , 50, 572-580	36.3	82
86	Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3. <i>Circulation</i> , 2018 , 137, 975-977	16.7	68
85	Genetics of coronary artery disease. <i>Annual Review of Genomics and Human Genetics</i> , 2010 , 11, 91-108	9.7	67
84	Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2 Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1472-1479	9.4	62

83	Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e000067	5.2	59
82	Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells. <i>Cell Stem Cell</i> , 2016 , 18, 73-78	18	57
81	Genome editing in cardiovascular diseases. <i>Nature Reviews Cardiology</i> , 2017 , 14, 11-20	14.8	57
80	Stem cell models of cardiac development and disease. <i>Annual Review of Cell and Developmental Biology</i> , 2010 , 26, 667-87	12.6	53
79	Role of angiotensin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. <i>Atherosclerosis</i> , 2018 , 268, 196-206	3.1	52
78	In utero gene editing for monogenic lung disease. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	51
77	Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 445-53		48
76	Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 448-467		37
75	Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells. <i>Development (Cambridge)</i> , 2016 , 143, 1475-81	6.6	36
74	Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 216-42		33
73	NLRP2 is a suppressor of NF- κ B signaling and HLA-C expression in human trophoblasts. <i>Biology of Reproduction</i> , 2017 , 96, 831-842	3.9	31
72	The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 914-919	16.2	30
71	Transcriptome-Wide Analysis Reveals Modulation of Human Macrophage Inflammatory Phenotype Through Alternative Splicing. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 1434-47	9.4	30
70	Genome-Edited Human Pluripotent Stem Cell-Derived Macrophages as a Model of Reverse Cholesterol Transport--Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 15-8	9.4	27
69	Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies. <i>Frontiers in Immunology</i> , 2015 , 6, 250	8.4	27
68	ESRP1 Mutations Cause Hearing Loss due to Defects in Alternative Splicing that Disrupt Cochlear Development. <i>Developmental Cell</i> , 2017 , 43, 318-331.e5	10.2	26
67	Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.. <i>Cell</i> , 2022 , 185, 250-265.e166		26
66	Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. <i>Cell Stem Cell</i> , 2021 , 28, 938-954.e9	18	23

65	Interrogation of the Atherosclerosis-Associated (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 76-82	9.4	23
64	Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes. <i>Circulation</i> , 2018 , 138, 2852-2854	16.7	23
63	Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 213-6	4.8	22
62	Genome engineering tools for building cellular models of disease. <i>FEBS Journal</i> , 2016 , 283, 3222-31	5.7	21
61	Race, Natriuretic Peptides, and High-Carbohydrate Challenge: A Clinical Trial. <i>Circulation Research</i> , 2019 , 125, 957-968	15.7	21
60	Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. <i>PLoS ONE</i> , 2015 , 10, e0120295	3.7	21
59	Genetic and Chemical Screenings Identify HDAC3 as a Key Regulator in Hepatic Differentiation of Human Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2018 , 11, 22-31	8	20
58	Investigation of a dilated cardiomyopathy-associated variant in BAG3 using genome-edited iPSC-derived cardiomyocytes. <i>JCI Insight</i> , 2019 , 4,	9.9	20
57	Confirmation of Causal rs9349379- PHACTR1 Expression Quantitative Trait Locus in Human-Induced Pluripotent Stem Cell Endothelial Cells. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002327	5.2	19
56	Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e000062	5.2	18
55	Genome Editing for the Study of Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 2017 , 19, 22	4.2	17
54	Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing. <i>JACC Basic To Translational Science</i> , 2019 , 4, 755-762	8.7	17
53	Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002178	5.2	16
52	The clinical application of gene editing: ethical and social issues. <i>Personalized Medicine</i> , 2019 , 16, 337-350.	2	15
51	Genome Editing: The Recent History and Perspective in Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2808-2821	15.1	14
50	Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 503-504	15.2	14
49	CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 12-18	9.4	13
48	HapMap and mapping genes for cardiovascular disease. <i>Circulation: Cardiovascular Genetics</i> , 2008 , 1, 66-71		12

47	From Genotype to Phenotype. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11,	5.2	11
46	Functional evaluation of genetic variation in complex human traits. <i>Human Molecular Genetics</i> , 2012 , 21, R18-23	5.6	9
45	Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. <i>Journal of the American Heart Association</i> , 2012 , 1, e000554	6	9
44	Turning up the Heat with Therapeutic Epigenome Editing. <i>Cell Stem Cell</i> , 2018 , 22, 10-11	18	8
43	Rapid generation of novel models of RAG1 deficiency by CRISPR/Cas9-induced mutagenesis in murine zygotes. <i>Oncotarget</i> , 2016 , 7, 12962-74	3.3	8
42	From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2019 , 16, 157-167	2.8	7
41	Improving Genomic Literacy Among Cardiovascular Practitioners via a Flipped-Classroom Workshop at a National Meeting. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 287-90		7
40	Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e000046	5.2	7
39	Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 32	6	6
38	Enduring mystery of the chromosome 9p21.3 locus. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 224-5		6
37	Personalized genomes and cardiovascular disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014 , 5, a014068	5.4	5
36	Self-Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic Gene. <i>Hepatology Communications</i> , 2020 , 4, 1316-1331	6	5
35	In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease. <i>Nature Communications</i> , 2021 , 12, 4291	17.4	5
34	EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression. <i>iScience</i> , 2020 , 23, 100973	6.1	4
33	From Genotype to Phenotype: A Primer on the Functional Follow-up of Genome-Wide Association Studies in Cardiovascular Disease. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11,	5.2	4
32	Active learning-based STEM education for in-person and online learning. <i>Cell</i> , 2021 , 184, 1409-1414	56.2	4
31	Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2291-2303	15.1	4
30	Challenges and advances of CRISPR-Cas9 genome editing in therapeutics. <i>Cardiovascular Research</i> , 2019 , 115, e12-e14	9.9	3

29	Regulatory elements in noncoding DNA in the chromosome 9p21 locus. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 330-1		3
28	High-Throughput Screening and CRISPR-Cas9 Modeling of Causal Lipid-Associated Expression Quantitative Trait Locus Variants		3
27	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021 , 72, 447-458	17.4	3
26	Novel tricyclic glycal-based inducers that reprogram LDL metabolism in hepatic cells. <i>MedChemComm</i> , 2018 , 9, 1831-1842	5	3
25	Cardioprotective Effects of MTSS1 Enhancer Variants. <i>Circulation</i> , 2019 , 139, 2073-2076	16.7	2
24	Lack of association of KIF6 genotype with vascular disease and statin response. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 467-8		2
23	Moving toward genome-editing therapies for cardiovascular diseases.. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
22	Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects		2
21	Why Human Embryo Editing Should Be Banned. <i>CRISPR Journal</i> , 2019 , 2, 356-358	2.5	2
20	Stem cell modeling of lipid genetics. <i>Current Opinion in Lipidology</i> , 2018 , 29, 151-155	4.4	1
19	Transforming growth factor β mutations and familial thoracic aortic aneurysms. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 593-4		1
18	Current role of pharmacogenomics in cardiovascular medicine. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011 , 13, 302-12	2.1	1
17	Adipocyte-Specific Modulation of KLF14 Expression in Mice Leads to Sex-Dependent Impacts on Adiposity and Lipid Metabolism.. <i>Diabetes</i> , 2022 ,	0.9	1
16	Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver ANGPTL3 editing in wild-type and somatic LDLR knockout non-human primates		1
15	Therapeutic application of genome editing in dyslipidemia.. <i>Current Opinion in Lipidology</i> , 2021 , 33,	4.4	1
14	A synergistic relationship of elevated low-density lipoprotein cholesterol levels and systolic blood pressure with coronary artery calcification. <i>Atherosclerosis</i> , 2008 , 200, 368-73	3.1	0
13	Assessing for off-target mutagenesis 2021 , 81-100		0
12	CRISPR Hits Home in a First-in-Human Study. <i>CRISPR Journal</i> , 2021 , 4, 460-461	2.5	0

- 11 Mutations and Cardiovascular Function in Breast Cancer Survivors.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 833171 5.4 ○
- 10 Correcting tyrosinaemia via a point mutation. *Nature Biomedical Engineering*, **2020**, 4, 14-15 19
- 9 Identification of a growth factor that rejuvenates the heart. *Circulation: Cardiovascular Genetics*, **2013**, 6, 435-6
- 8 Induction of cardiomyocytes from cardiac fibroblasts. *Circulation: Cardiovascular Genetics*, **2012**, 5, 481-2
- 7 Exome sequencing to identify novel genes in hypertension. *Circulation: Cardiovascular Genetics*, **2012**, 5, 267-8
- 6 Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair. *Cell Stem Cell*, **2021**, 28, 2039-2040 18
- 5 Genome editing for cellular disease modeling **2021**, 145-167
- 4 Base editing **2021**, 101-121
- 3 Therapeutic genome editing **2021**, 193-211
- 2 Base editing: a brief review and a practical example. *Journal of Biomedical Research*, **2020**, 35, 107-114 1.5
- 1 Genome editing for functional experiments and screens **2021**, 169-191